| Date Filed | Type | Description |
| 03/16/2023 |
4
| Wiley Matthew T. (CHIEF COMMERCIAL OFFICER) has filed a Form 4 on BioXcel Therapeutics, Inc.|
Txns:
| Granted 12,000 restricted stock units
@ $0
Granted 36,000 options to buy
@ $19.6, valued at
$705.6k
|
|
| 01/19/2022 |
4
| Wiley Matthew T. (CHIEF COMMERCIAL OFFICER) has filed a Form 4 on BioXcel Therapeutics, Inc.|
Txns:
| Granted 85,000 options to buy
@ $19.5, valued at
$1.7M
|
|
| 01/19/2022 |
3
| Wiley Matthew T. (CHIEF COMMERCIAL OFFICER) has filed a Form 3 on BioXcel Therapeutics, Inc. |
| 07/02/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 04/02/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 02/24/2021 |
4
| Wiley Matthew T. (Chief Commercial Officer) has filed a Form 4 on VYNE Therapeutics Inc.|
Txns:
| Granted 27,675 shares
@ $0
Granted 64,575 options
@ $8.33, valued at
$537.9k
|
|
| 01/05/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 12/02/2020 |
4
| Wiley Matthew T. (Chief Commercial Officer) has filed a Form 4 on VYNE Therapeutics Inc.|
Txns:
| Granted 7,838 shares
@ $1.445, valued at
$11.3k
|
|
| 10/02/2020 |
4
| Wiley Matthew T. (Chief Commercial Officer) has filed a Form 4 on VYNE Therapeutics Inc.|
Txns:
| Paid exercise price by delivering 1,541 shares
@ $1.66, valued at
$2.6k
|
|
| 07/02/2020 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 05/08/2020 |
4
| Wiley Matthew T. (Chief Commercial Officer) has filed a Form 4 on Menlo Therapeutics Inc.|
Txns:
| Granted 150,000 shares
@ $0
Granted 150,000 options
@ $1.95, valued at
$292.5k
|
|
| 04/07/2020 |
4
| Wiley Matthew T. (Chief Commercial Officer) has filed a Form 4 on Menlo Therapeutics Inc.|
Txns:
| Granted 46,394 shares
@ $0
Granted 91,430 shares
@ $0
Paid exercise price by delivering 908 shares
@ $1.4, valued at
$1.3k
|
|
| 04/02/2020 |
4
| Wiley Matthew T. (Chief Commercial Officer) has filed a Form 4 on Menlo Therapeutics Inc.|
Txns:
| Paid exercise price by delivering 525 shares
@ $2.68, valued at
$1.4k
|
|
| 03/11/2020 |
4
| Wiley Matthew T. (Chief Commercial Officer) has filed a Form 4 on Menlo Therapeutics Inc.|
Txns:
| Granted 20,896 shares
@ $0
Granted 46,680 shares
@ $0
Granted 59,240 options
@ $6.86, valued at
$406.4k
Granted 57,086 options
@ $6.81, valued at
$388.8k
|
|
| 03/11/2020 |
3
| Wiley Matthew T. (Chief Commercial Officer) has filed a Form 3 on Menlo Therapeutics Inc. |
| 03/11/2020 |
4
| Wiley Matthew T. (Chief Commercial Officer) has filed a Form 4 on Foamix Pharmaceuticals Ltd.|
Txns:
| Disposed/sold 35,275 shares
@ $0
Disposed/sold 78,799 shares
@ $0
Disposed/sold 100,000 options
@ $4.06, valued at
$406k
Disposed/sold 96,365 options
@ $4.03, valued at
$388.4k
|
|
| 03/03/2020 |
4
| Wiley Matthew T. (Chief Commercial Officer) has filed a Form 4 on Foamix Pharmaceuticals Ltd.|
Txns:
| Granted 1,993 shares
@ $2.6775, valued at
$5.3k
|
|
| 02/24/2020 |
4
| Wiley Matthew T. (Chief Commercial Officer) has filed a Form 4 on Foamix Pharmaceuticals Ltd.|
Txns:
| Granted 41,299 shares
@ $0
Granted 96,365 options to buy
@ $4.03, valued at
$388.4k
|
|
| 01/03/2020 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 12/03/2019 |
4
| Wiley Matthew T. (Chief Commercial Officer) has filed a Form 4 on Foamix Pharmaceuticals Ltd.|
Txns:
| Granted 9,842 shares
@ $2.159, valued at
$21.2k
|
|
| 03/06/2019 |
4
| Wiley Matthew T. (Chief Commercial Officer) has filed a Form 4 on Foamix Pharmaceuticals Ltd.|
Txns:
| Bought 13,440 shares
@ $3.76, valued at
$50.5k
|
|
| 12/04/2018 |
4
| Wiley Matthew T. (Chief Commercial Officer) has filed a Form 4 on Foamix Pharmaceuticals Ltd.|
Txns:
| Granted 50,000 shares
@ $0
Granted 100,000 options to buy
@ $4.06, valued at
$406k
|
|
| 11/26/2018 |
3
| Wiley Matthew T. (Chief Commercial Officer) has filed a Form 3 on Foamix Pharmaceuticals Ltd. |